About: Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.51 (-5.03%)
PALI NASDAQ Palisade Bio Inc
Palisade Bio Inc share price
PALI price activity
Last Price
$1.510
Change (24hr)
-0.08 USD (-5.03%)
Volume
764.67K
Volume (4w avg)
-
Open
$1.56
Day Range
$1.51 - $1.56
Previous Close
$1.59
Last Trade
13 Oct, 5:34 pm GMT+0
Delayed
13 Oct, 5:34 pm GMT+0
PALI price performance
Delayed
13 Oct, 5:34 pm GMT+0
PALI Market Signals